RT Journal Article
T1 Reactive astrocyte nomenclature, definitions, and future directions.
A1 Escartin, Carole
A1 Galea, Elena
A1 Lakatos, András
A1 O'Callaghan, James P
A1 Petzold, Gabor C
A1 Serrano-Pozo, Alberto
A1 Steinhäuser, Christian
A1 Volterra, Andrea
A1 Carmignoto, Giorgio
A1 Agarwal, Amit
A1 Allen, Nicola J
A1 Araque, Alfonso
A1 Barbeito, Luis
A1 Barzilai, Ari
A1 Bergles, Dwight E
A1 Bonvento, Gilles
A1 Butt, Arthur M
A1 Chen, Wei-Ting
A1 Cohen-Salmon, Martine
A1 Cunningham, Colm
A1 Deneen, Benjamin
A1 De Strooper, Bart
A1 Díaz-Castro, Blanca
A1 Farina, Cinthia
A1 Freeman, Marc
A1 Gallo, Vittorio
A1 Goldman, James E
A1 Goldman, Steven A
A1 Götz, Magdalena
A1 Gutiérrez, Antonia
A1 Haydon, Philip G
A1 Heiland, Dieter H
A1 Hol, Elly M
A1 Holt, Matthew G
A1 Iino, Masamitsu
A1 Kastanenka, Ksenia V
A1 Kettenmann, Helmut
A1 Khakh, Baljit S
A1 Koizumi, Schuichi
A1 Lee, C Justin
A1 Liddelow, Shane A
A1 MacVicar, Brian A
A1 Magistretti, Pierre
A1 Messing, Albee
A1 Mishra, Anusha
A1 Molofsky, Anna V
A1 Murai, Keith K
A1 Norris, Christopher M
A1 Okada, Seiji
A1 Oliet, Stéphane H R
A1 Oliveira, João F
A1 Panatier, Aude
A1 Parpura, Vladimir
A1 Pekna, Marcela
A1 Pekny, Milos
A1 Pellerin, Luc
A1 Perea, Gertrudis
A1 Pérez-Nievas, Beatriz G
A1 Pfrieger, Frank W
A1 Poskanzer, Kira E
A1 Quintana, Francisco J
A1 Ransohoff, Richard M
A1 Riquelme-Perez, Miriam
A1 Robel, Stefanie
A1 Rose, Christine R
A1 Rothstein, Jeffrey D
A1 Rouach, Nathalie
A1 Rowitch, David H
A1 Semyanov, Alexey
A1 Sirko, Swetlana
A1 Sontheimer, Harald
A1 Swanson, Raymond A
A1 Vitorica, Javier
A1 Wanner, Ina-Beate
A1 Wood, Levi B
A1 Wu, Jiaqian
A1 Zheng, Binhai
A1 Zimmer, Eduardo R
A1 Zorec, Robert
A1 Sofroniew, Michael V
A1 Verkhratsky, Alexei
AB Reactive astrocytes are astrocytes undergoing morphological, molecular, and functional remodeling in response to injury, disease, or infection of the CNS. Although this remodeling was first described over a century ago, uncertainties and controversies remain regarding the contribution of reactive astrocytes to CNS diseases, repair, and aging. It is also unclear whether fixed categories of reactive astrocytes exist and, if so, how to identify them. We point out the shortcomings of binary divisions of reactive astrocytes into good-vs-bad, neurotoxic-vs-neuroprotective or A1-vs-A2. We advocate, instead, that research on reactive astrocytes include assessment of multiple molecular and functional parameters-preferably in vivo-plus multivariate statistics and determination of impact on pathological hallmarks in relevant models. These guidelines may spur the discovery of astrocyte-based biomarkers as well as astrocyte-targeting therapies that abrogate detrimental actions of reactive astrocytes, potentiate their neuro- and glioprotective actions, and restore or augment their homeostatic, modulatory, and defensive functions.
YR 2021
FD 2021-02-15
LK http://hdl.handle.net/10668/17184
UL http://hdl.handle.net/10668/17184
LA en
DS RISalud
RD Apr 7, 2025